Duration of Effect of Acidform Gel on Vaginal pH
A Randomized, Placebo Controlled Pilot Study to Determine the Effect and Duration of Acidform Gel on Vaginal pH
調査の概要
詳細な説明
One hundred healthy volunteer women, 20 per each treatment arm, were treated with either Intravaginal Acidform Gel(IVAG), 5 g dose (GROUP A), Acidform gel, 4 g dose (GROUP B), Acidform gel, 3 g dose (GROUP C), Universal Placebo Gel (UPG), 4 g (GROUP D) or no treatment (GROUP E). For GROUPS A, B, C and D, treatment is defined as speculum exam plus instillation of Investigational Product (IP) or placebo gel. For GROUP E (control), no treatment is defined as speculum exam and no gel instillation.
At least 15 women in each group were of either African American or Hispanic ethnicity. Routine screening tests were performed on admission; and subjects assessed for BV via vaginal swabs obtained for grading by Amsel criteria.
A direct vaginal pH reading by research staff- was obtained before the speculum exam, as well as one hour, and six hours post-treatment (Day 0). At the one hour and six hour post treatment time points, the direct vaginal pH readings were taken on specimens collected from two different positions in the vagina, in case of incomplete distribution of the IP soon after administration. Both readings are included as data points. At the six hour timepoint, subjects were trained on self-collecting vaginal swabs and performing the vaginal pH test. At 12 hours post-treatment, subjects performed the vaginal pH test themselves using self-obtained swabs, and record their results for clinician review.
Subjects stayed overnight in the domiciliary unit, and vaginal pH and Amsel criteria was measured again by research staff at 24 (+/- 2) hours post-treatment before discharge on Day 1. The subjects were discharged with the appropriate pH testing supplies and diary. All women agreed to abstain from sexual intercourse, douching and use of any intravaginally applied products or devices until after their final study visit on Day 7.
Subjects measured their vaginal pH at 24 (+/-2) hour intervals for 5 days (Days 2-6) as outpatients and recorded the pH test results, and any change in vaginal comfort, in a provided diary. Subjects also recorded any activities engaged in from the abstinence criteria in the study exclusion list, if applicable, each day. On Day 7, subjects returned to the clinic with their diaries, had their vaginal pH and Amsel criteria determined by the clinic staff, and queried as to any vaginal discomfort (vaginal comfort assessment) over the course of the study, as self-recorded in their diaries.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21224
- Johns Hopkins Bayview Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44109
- Metro Health Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy female subjects between 18 and 45 years, inclusive
- Ability to understand the consent process and procedures
- Subjects agree to be available for all study visits
- Written informed consent in accordance with institutional guidelines
- Negative pregnancy test
- Able and willing to comply with all study procedures
- Have not engaged in sexual intercourse, douching or used of any form of vaginal suppository or intravaginal device for 24 hours prior to enrollment.
- Agree to abstain from sexual intercourse, douching or any form of vaginal suppository or intravaginal device use during course of study
- Report menstrual cycle regularity (25- to 35- day menstrual cycles)
Exclusion Criteria:
- Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study protocol
- Any other medical condition(s) that, in the judgment of the investigator, might interfere with the study or require treatment that might interfere with the study
- Family member of the investigation study staff
- Pregnant or breast-feeding
- Inability to provide informed consent
- A subject with a history or expectation of noncompliance with medications or treatment protocol
- Women with symptoms of Urinary Tract Infection (UTI) or Sexually Transmitted Infection (STI) reported or observed during examination, at screening*.
- Women who regularly use douches, vaginal medications or suppositories, feminine sprays, genital wipes or contraceptive spermicides, or report abnormal vaginal discharge in the past 48 hours prior to screening
- Women who are menstruating or who would expect to menstruate during the study
- Women who are currently using contraceptives that are directly delivered to the vaginal mucosa, such as NuvaRing
- Any specific condition that, in the judgment of the Investigator, precludes participation because it could affect subject safety
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Acidform Gel, Group A
Administration of a single vaginal dose of Acidform gel (5 g)
|
Effect of 5 g vaginally administered Acidform on pH over 7 days
|
実験的:Acidform Gel, Group B
Administration of a single vaginal dose of Acidform gel (4 g)
|
Effect of 4 g vaginally administered Acidform on pH over 7 days
|
実験的:Acidform Gel, Group C
Administration of a single vaginal dose of Acidform gel (3 g)
|
Effect of 3 g vaginally administered Acidform on pH over 7 days
|
プラセボコンパレーター:Placebo Gel, Group D
Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
|
Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
他の名前:
|
介入なし:No intervention, Group E
No vaginal product administered
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention.
時間枠:Baseline (Day 0), 1, 6 & 12 hours post treatment, and Days 1, 2, 3, 4, 5, 6 & 7.
|
Vaginal swabs were used to collect samples from the vagina of women dosed with Acidform, HEC placebo, or no treatment.
The pH of the samples was measured at pre-determined time points over the course of 7 days.
|
Baseline (Day 0), 1, 6 & 12 hours post treatment, and Days 1, 2, 3, 4, 5, 6 & 7.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
The Effect of a Single Dose of Acidform Gel (3, 4 or 5 g), Placebo Gel (4 g), or no Treatment on Asymptomatic Bacterial Vaginosis (BV) Based on Amsel Criteria.
時間枠:Baseline (Day 0), Day 1 and Day 7
|
Amsel Criteria was used at baseline (day 0), compared to Day1 and Day 7 following the single dose of Acidform or placebo.
Amsel criteria assessments consisted of Yes/No indications for the presence of each of the following: Vaginal pH> 4.5; Presence of thin, grayish white vaginal discharge; Positive wet prep; Positive whiff amine test.
Based on the individual criteria, a derived overall result (positive/negative) was reported.
Amsel Result was automatically calculated based whether or not subject is positive in three of the four criteria listed above.
|
Baseline (Day 0), Day 1 and Day 7
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ann Avery, MD、Metro Health Medical Center
- 主任研究者:Seema Nayak, MD、Johns Hopkins University
- スタディディレクター:John M Griffiss, MD、Clinical Research Management, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- EVO-002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Acidform 5 gの臨床試験
-
AlgiPharma ASSmerud Medical Research International AS完了
-
Scottish Universities Environmental Research CentreBiotechnology and Biological Sciences Research Council; University of Glasgow完了
-
Idorsia Pharmaceuticals Ltd.完了